“The main problem with this study,” he concludes, “is the relatively short follow-up time considering these conditions take years to develop.”
Reference
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
- Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs. TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019 Mar 27. [Epub ahead of print]